GTB-7550 / GT Biopharma - LARVOL DELTA

Combinational Natural Killer Cell- Based Therapies Treating Rituximab- Resistant Burkitt Lymphoma (ASPHO 2025) - "Obinutuzumab (OB) is a glycoengineered humanized type-II mAb recognizing a unique CD20 epitope with significantly enhanced antibody-dependent cellular cytotoxicity than rituximab. Our results demonstrated the efficacy of combinatorial NK immunotherapy in treating rituximab-resistant BL cells. Our future studies will determine the in vivo efficacy of NK in combination with cam161519 and OB, and CD20.CAR NK in combination with cam161519 or NKTR-255 in resistant BL models."

Burkitt Lymphoma • Hematological Malignancies • Lymphoma • Oncology • IFNG • IL15